1-Boc-4-(氰基甲基)哌啶 | 256411-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-Boc-4-(氰基甲基)哌啶
• 中文别名: N-Boc-4-哌啶乙腈；N-Boc-4-氰基甲基哌啶；(1-叔丁氧羰基哌啶-4-基)乙腈；1-BOC-4-氰基甲基哌啶；4-腈甲基-1-N-Boc-哌啶
• 英文名称: tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate
• 英文别名: N-Boc-4-(cyanomethyl)piperidine
• CAS: 256411-39-9
• 化学式: C₁₂H₂₀N₂O₂
• mdl: MFCD09801019
• 分子量: 224.303
• InChiKey: LARQASBBVGBMDA-UHFFFAOYSA-N

物化性质

• 沸点：
  344.3±15.0 °C(Predicted)
• 密度：
  1.040±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  53.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-4-cyanomethylpiperidine
Synonyms: Tert-Butyl 4-(cyanomethyl)piperidine-1-carboxylate; (1-BOC-piperidin-4-yl)acetonitrile

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-4-cyanomethylpiperidine
CAS number: 256411-39-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H20N2O2
Molecular weight: 224.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-4-(氰基甲基)哌啶 在 盐酸羟胺 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 6.5h， 生成 4-(羟基亚氨基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  Substituted homopiperidine, piperidine or pyrrolidine derivatives

  摘要：

  一种新型的取代的同环丙啶、哌啶和吡咯啶衍生物类别，其制备方法，包含它们的药物组合物以及在治疗与组胺H3受体相关的疾病中的应用。更具体地说，这些化合物具有组胺H3受体拮抗活性，因此在组胺H3受体阻滞有益的疾病治疗中是有用的。

  公开号：

  US20050107434A1
• 作为产物：
  描述：

  4-(2-氧代乙基)哌啶-1-羧酸叔丁酯 在 二苯基膦酰羟胺 作用下， 以 甲苯 为溶剂， 以92%的产率得到1-Boc-4-(氰基甲基)哌啶
  参考文献：
  名称：

  醛到腈的化学选择性一锅转化

  摘要：

  本文介绍了使用O-（二苯基膦基）羟胺（DPPH）将醛直接转化为腈的方法。通过在甲苯中与DPPH一起加热，可以将醛平稳地转化为相应的腈。该反应可以在醇，酮，酯或胺官能团的存在下完成。

  DOI：

  10.1021/jo301133y

文献信息

• Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
  申请人：Goble D. Stephen

  公开号：US20070238723A1

  公开（公告）日：2007-10-11

  Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

  环戊基化合物通过酰胺基团与苯并噁唑基团相连，利用苯并噁唑环的环氮原子，并进一步用杂环基团取代，这些化合物由式I表示： 用于调节CCR-2趋化因子受体，以预防或治疗炎症和免疫调节性疾病和疾病，过敏性疾病，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理病变；以及包含这些化合物的药物组合物和这些化合物和组合物的使用。
• Nitrogen containing heterocyclic compounds and medicines containing the same
  申请人：——

  公开号：US20040167224A1

  公开（公告）日：2004-08-26

  Compounds represented by the following general formula: 1 (wherein X 1 , X 2 , X 3 and X 4 each independently represent a single bond, C 1-6 alkylene, etc.; A 2 represents optionally substituted phenyl, etc.; A 1 represents an optionally substituted 5- to 7-membered heterocyclic group containing —C(═Q 1 )— (wherein Q 1 represents oxygen, sulfur or ═N—R 11 (wherein R 11 represents hydrogen or C 1-6 alkyl)) and nitrogen, etc.; and Z 1 represents piperidin-diyl, etc.), salts thereof and hydrates of the foregoing.

  由以下一般式表示的化合物： 1 （其中X 1 、X 2 、X 3 和X 4 分别独立表示单键，C 1-6 烷基等；A 2 表示可选择地取代的苯基等；A 1 表示可选择地取代的含有—C(═Q 1 )—的5-至7-成员杂环基团（其中Q 1 表示氧、硫或═N—R 11 （其中R 11 表示氢或C 1-6 烷基））和氮等；以及Z 1 表示哌啶二基等），以及其盐和上述化合物的水合物。
• Transformation of aldehydes into nitriles in an aqueous medium using O-phenylhydroxylamine as the nitrogen source
  作者：Thamrongsak Cheewawisuttichai、Robert D. Hurst、Matthew Brichacek

  DOI：10.1016/j.carres.2021.108282

  日期：2021.4

  The conversion of an aldehyde into a nitrile can be efficiently performed using O-phenylhydroxylamine hydrochloride in buffered aqueous solutions. The reported method is specifically optimized for aqueous-soluble substrates including carbohydrates. Several reducing sugars including monosaccharides, disaccharides, and silyl-protected saccharides were transformed into cyanohydrins in high yields. The

  在缓冲水溶液中使用O-苯基羟胺盐酸盐可以有效地将醛转化为腈。报告的方法专门针对包括碳水化合物在内的水溶性底物进行了优化。包括单糖、二糖和甲硅烷基保护的糖在内的几种还原糖以高产率转化为氰醇。反应条件也适用于从各种类型的疏水醛底物形成腈。此外，通过使用易于去除的弱碱性树脂作为促进剂，可以从氰醇中消除氰化物，类似于 Wohl 降解。
• Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors
  作者：Anže Meden、Damijan Knez、Natalia Malikowska-Racia、Xavier Brazzolotto、Florian Nachon、Jurij Svete、Kinga Sałat、Uroš Grošelj、Stanislav Gobec

  DOI：10.1016/j.ejmech.2020.112766

  日期：2020.12

  A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal

  设计并合成了一系列基于色氨酸的选择性纳摩尔丁酰胆碱酯酶（BChE）抑制剂。在效价，选择性和合成可及性方面对化合物进行了优化。与BChE配合的抑制剂18的晶体结构揭示了其低纳摩尔抑制作用的分子基础（IC 50  = 2.8 nM）。良好的体外结果使得首次在动物体内进行了有效性和安全性试验，证明了对恐惧驱动的空间长期记忆恢复的积极影响，而没有任何伴随的不良运动影响。总而言之，这项研究最终产生了一些新的铅化合物，这些化合物有望在对症治疗阿尔茨海默氏病的过程中大有前途。
• [EN] QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE QUINOLÉINE ET DE QUINAZOLINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：STINGRAY THERAPEUTICS INC

  公开号：WO2020190912A1

  公开（公告）日：2020-09-24

  Compounds and methods for their preparation and use as therapeutic or prophylactic agents, fo example for treatment of cancer, bacterial or viral diseases by targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase- 1 (ENPP1).

  化合物及其制备和用作治疗或预防剂的方法，例如通过靶向Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1)来治疗癌症、细菌或病毒性疾病。